ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
Pace ® is happy to share news from our client, ReveraGen BioPharma Inc., on a significant accomplishment! ReveraGen Completes NDA […]
Uncategorized
Life Sciences
Uncategorized
Pace® Life Sciences Acquires Biopharma Global, Expanding FDA Regulatory Affairs Strategy and Consulting Capabilities to the Biotechnology and Pharmaceutical Markets
Acquisition allows Pace® to provide full-service regulatory strategy and consulting services to advance FDA submissions across a wide range of
Uncategorized
First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation
First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First
Uncategorized
First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract
Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc.,
Uncategorized
Pace® Life Sciences Acquires Meridian BioGroup, Expanding Regulatory, Compliance, and Validation Capabilities to the Biotechnology and Pharmaceutical Markets
Acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve
Uncategorized
Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Sustainability Efforts
Company excels in Labor & Human Rights and Ethics performance for current Corporate Social Responsibility (CSR) Initiatives. Pace® Life Sciences,
Webinar: The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf
Pharmaceutical Technology hosts “The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf” – a webinar
Uncategorized
Getting Drugs to Market – Dr Frank Tagliaferri, Pace Life Sciences
Frank Tagliaferri, Ph.D., Vice President of Pharmaceutical Development sat down with BioProcess International to discuss the growth the industry, and
Uncategorized
The Changing Landscape of Gene Therapy
Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Biocompare, The Buyer’s Guide for Life Sciences Published an Article: The
Uncategorized
Pace® Life Sciences Acquires Velesco Pharmaceutical Services
Acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use